Search
for
Sort by
Research 121–150 of 132
- Dermatology Benefits of Licorice (Glycyrrhiza glabra L.): A Review of its Potential in Skin and Hair Disorders
- Finasteride, pharmacogenomics, and suicide risk: a public health concern
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Optimization of Nanostructured Lipid Carriers (NLC) Extract Crude Fucoidan Algae Brown (Sargassum chrysanthemum): Design and Characterization
- Commonly encountered symptoms and their management in patients with cirrhosis
- From bench to babies – drug development for male subfertility
- Enhancing Solubility and Dissolution Behavior of Finasteride Using Solid Dispersion Technique by Carrier Screening and the New Preparation Instrument
- Lower urinary tract symptoms (LUTS): The role of medications in improvement of quality of life
- Anti-inflammatory Effects in LPS-treated RAW 264.7 Cells and the Influences on Drug Metabolizing Enzyme Activities by the Traditional Herbal Formulas, Yongdamsagan-Tang and Paljung-san
- Geographical Differences in Male Infertility between the United States and Canada: Insights from the Andrology Research Consortium
- Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
- Case report: a study of the clinical characteristics and genetic variants of post-finasteride syndrome patients
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Selective and rapid determination of tadalafil and finasteride using solid phase extraction by high performance liquid chromatography and tandem mass spectrometry
- Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
- Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
- Drug–Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance
- Drug–DrugCoamorphous System of Tadalafil andFinasteride for Enhanced Pharmaceutical Performance
- RP-HPLC-Based Stability-Indicating Analytical Method for Concurrent Determination of Finasteride and Tadalafil: Development and Validation
- BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF FINASTERIDE, TADALAFIL, AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RAT PLASMA BY USING LC-MS/MS
- Synchronous fluorescence as a green and selective method for the simultaneous determination of finasteride and tadalafil in dosage form and spiked human plasma
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools
- A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
- New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
- An Innovative Reverse-Phase High-Performance Liquid Chromatography Technique For Measuring Finasteride And Tadalafil In Raw Materials And Pharmaceutical Products With Stability Indication
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Medikamentöse Therapie des benignen Prostatasyndroms
- 1194: The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study
- Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments